$ADGI News
Last published 3y ago
- 3y agoIVVDADGIInvivyd to Participate at Cowen's 43rd Annual Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David
- 3y agoIVVDADGIInvivyd Announces Changes to Executive TeamGlobeNewswireWALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today announced that Laura
- 3y agoIVVDADGIInvivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA WorkshopGlobeNewswireWALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to
- 3y agoIVVDADGIInvivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical OfficerGlobeNewswireWALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the
- 3y agoIVVDADGIInvivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19GlobeNewswire-Broad partnership will strengthen Invivyd's development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and beyond- -Population
- 4y agoADGIIVVDInvivyd Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewswireNovel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support operating runway into Q2
- 4y agoADGIIVVDInvivyd to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David
- 4y agoADGIIVVDInvivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewswireWALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced that it
- 4y agoIVVDADGIInvivyd Announces the Appointment of Christine Lindenboom to Board of DirectorsGlobeNewswireWALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the
- 4y agoIVVDADGIInvivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery PlatformGlobeNewswireWALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the
- 4y agoIVVDADGIInvivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022GlobeNewswireWALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (NASDAQ:IVVD), formerly Adagio Therapeutics (NASDAQ:ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral
- 4y agoADGIIVVDInvivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron VariantsGlobeNewswireIntegrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern (e.g., D614G, beta, delta) and Omicron sublineages BA.1, BA.2, BA.4, BA.5 and BA.2.75, as well as SA
- 4y agoADGIIVVDAdagio Therapeutics Announces Corporate Name Change to InvivydGlobeNewswireNew name reflects Company focus on leveraging its integrated discovery platform to generate anti-viral antibodies that transcend the limits of naturally occurring immunity The Invivyd corporate mission is to provide antibody solutions that provide supe
- 4y agoADGIAdagio Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ:ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatme
- 4y agoADGIAdagio Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsGlobeNewswire$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New Candidates for COVID-19 Prevention and Treatment with Plans to Enter Clinical Trials in the First Q
- 4y agoADGIMithril Capital's Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy CampaignBusiness WireAdagio Shareholders Overwhelmingly Elected Mithril's Three High-Quality Director Candidates To the Adagio Board Board Transformation will Advance Company's Mission to Prevent and Treat COVID19 and Other Infectious Diseases Mithril Capital Manageme
- 4y agoADGIAdagio Announces David Hering Named Permanent Chief Executive Officer and DirectorGlobeNewswireWALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ:ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, annou
- 4y agoADGIAdagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of DirectorsGlobeNewswireWALTHAM, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ:ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, annou
- 4y agoADGIAdagio Therapeutics Reports First Quarter 2022 Financial ResultsGlobeNewswire$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024 Additional Data from Adintrevimab Phase 2/3 STAMP Treatment Trial to be Presented at ASM Annual Meeting WALTHAM, Mass., May 1
- 4y agoADGIAdagio Therapeutics Provides Update on Timing of Adintrevimab EUA RequestGlobeNewswireWALTHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ:ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, rece
- 4y agoADGIAdagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use AuthorizationGlobeNewswireRisk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis Risk of hospitalization or death in participants with mild to moderate COVID-19 was reduced by
- 4y agoADGIAdagio Therapeutics, Inc. Announces 2022 Annual Meeting of StockholdersGlobeNewswireWALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ:ADGI) today announced that it will hold its 2022 Annual Meeting of Stockholders virtually at 8:30 a.m. Eastern Time on May 26, 2022. Additional information regarding t
- 4y agoADGIAdagio Therapeutics Announces David Hering Appointed Interim Chief Executive OfficerGlobeNewswireWALTHAM, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with
- 4y agoADGIAdagio Therapeutics Announces ADG20 Development Plans and Pipeline UpdatesGlobeNewswireMultiple Initiatives Undertaken for ADG20 Assessment, Including Analysis of Clinical Data at 300mg Dose and Exploring Higher Doses of ADG20 in the Clinic Company Pursuing Portfolio of Antibodies in Response to Continuously Emerging SARS-CoV-2 Variants
- 4y agoADGIAdagio Therapeutics Announces CEO Succession PlanGlobeNewswireWALTHAM, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ:ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with p
- 4y agoADGIBTCSMATPETV+1Thinking about buying stock in Adagio Therapeutics, Vyne Therapeutics, PetVivo, BTCS Inc, or Mattel?PR NewswireNEW YORK, Jan. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, VYNE, PETV, BTCS, and MAT.
- 4y agoADGIAdagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address OmicronGlobeNewswireRecent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron Multiple Efforts Underway to Address Omicron and Potential Future SARS-CoV-2
- 4y agoADGIAdagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with p
- 4y agoADGIBRFSEFOIRBOT+1Thinking about buying stock in Adagio Therapeutics, Wireless Telecom, BRF S.A., Energy Focus, or Vicarious Surgical?PR NewswireNEW YORK, Dec. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, WTT, BRFS, EFOI, and RBOT.
- 4y agoADGIICVXIKNAIMGO+5Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science CompaniesPR NewswireBOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million in limited part
- 4y agoADGICLFENSCLAZR+1Thinking about buying stock in Luminar Technologies, Cleveland-Cliffs, Pulmatrix, Adagio Therapeutics, or Ensysce Biosciences?PR NewswireNEW YORK, Dec. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LAZR, CLF, PULM, ADGI, and ENSC.
- 4y agoADGIAVCTHOODNES+1Thinking about buying stock in SeaChange, Nuverra Environmental Solutions, Adagio Therapeutics, American Virtual Cloud Technologies, or Robinhood Markets?PR NewswireNEW YORK, Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEAC, NES, ADGI, AVCT, and HOOD.
- 4y agoADGIAdagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 VariantGlobeNewswireWALTHAM, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with p
- 4y agoADGIATHXFWBIIMGN+1Thinking about buying stock in Adagio Therapeutics, Pioneer Power Solutions, ImmunoGen, Athersys, or First Wave BioPharma?PR NewswireNEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, PPSI, IMGN, ATHX, and FWBI.
- 4y agoADGIATNFBYSIINM+1Thinking about buying stock in Adagio Therapeutics, 180 Life Sciences, InMed Pharmaceuticals, Beyondspring, or Inovio Pharmaceuticals?PR NewswireNEW YORK, Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, ATNF, INM, BYSI, and INO. To
- 4y agoADGIAdagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In VitroGlobeNewswireAdditional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing ADG20 EUA submissions planned for prevention and treatment of COVID-19 in mid-2022 Inventory build continues in anticipation of EUA in second half
- 4y agoADGINVAXBNTXPFE+1Moderna Surges After Saying Omicron Vaccine Ready Early 2022Bloomberg
- 4y agoADGIAdagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19GlobeNewswireWALTHAM, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with p
- 4y agoADGIAdagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial ResultsGlobeNewswireFDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID-19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second Quarter 2022 Enrollment Progressing
- 5y agoADGIAdagio Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with p
- 5y agoADGIAdagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 VariantsGlobeNewswireWALTHAM, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with p
- 5y agoREGNABCLINOADGI+4Vaccine Stocks Shed $84 Billion as Merck Pill Adds to Rough WeekBloomberg
- 5y agoADGIAdagio Therapeutics to Participate in the Guggenheim 2nd Annual Vaccines & Infectious Day ConferenceGlobeNewswireWALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with
- 5y agoADGIAdagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19GlobeNewswireADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study Data from Quantitative Systems Pharmacology/Whole-Body Physiologically Base
- 5y agoADGIAdagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial ResultsGlobeNewswireNew Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021 Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded following IDMC Assessment $355.8 Million IPO Comp
- 5y agoADGIAdagio Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with